A case report of a patient with refractory adult-onset Still's disease who was successfully treated with tocilizumab over 6 years.

Abstract

Interleukin-6 overproduction is pathologically involved in adult onset Still's disease (AOSD). We successfully treated a man with refractory AOSD utilizing tocilizumab. Tocilizumab was discontinued after 15 doses due to intestinal bleeding, but the efficacy was sustained over 21 months. Tocilizumab was readministered safely upon recurrence and showed similar efficacy over 6 years. Corticosteroid and NSAIDs could be discontinued and intestinal bleeding was no more observed. Tocilizumab can be a therapeutic option for AOSD.

• Authors: Hideko Nakahara, Toru Mima, Naoko Yoshio-Hoshino, Masato Matsushita, Jun Hashimoto, Norihiro Nishimoto
• Journal: Modern rheumatology (Mod Rheumatol) Vol. 19 Issue 1 Pg. 69-72 ( 2009) ISSN: 1439-7595 [Print] England
• PMID: 18762861 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• tocilizumab

Topics

• Antibodies, Monoclonal (administration & dosage, therapeutic use)
• Antibodies, Monoclonal, Humanized
• Dose-Response Relationship, Drug
• Follow-Up Studies
• Humans
• Male
• Remission Induction (methods)
• Still's Disease, Adult-Onset (drug therapy)
• Time Factors
• Young Adult